{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T02:59:37Z","timestamp":1783047577377,"version":"3.54.6"},"reference-count":27,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2020.8204","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T15:42:52Z","timestamp":1594050172000},"page":"e208204","source":"Crossref","is-referenced-by-count":16,"title":["Association of Innovations in Radiotherapy and Systemic Treatments With Clinical Outcomes in Patients With Melanoma Brain Metastasis From 2007 to 2016"],"prefix":"10.1001","volume":"3","author":[{"given":"Harry C.","family":"Brastianos","sequence":"first","affiliation":[{"name":"Department of Oncology, Queen\u2019s University, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nguyen","sequence":"additional","affiliation":[{"name":"ICES, Queen\u2019s University, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun","family":"Sahgal","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Sunnybrook Odette Cancer Center, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Eisenhauer","sequence":"additional","affiliation":[{"name":"Department of Oncology, Queen\u2019s University, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Baetz","sequence":"additional","affiliation":[{"name":"Department of Oncology, Queen\u2019s University, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy P.","family":"Hanna","sequence":"additional","affiliation":[{"name":"Department of Oncology, Queen\u2019s University, Kingston, Ontario, Canada"},{"name":"ICES, Queen\u2019s University, Kingston, Ontario, Canada"},{"name":"Division of Cancer Care and Epidemiology, Cancer Research Institute, Queen\u2019s University, Kingston, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2020,7,6]]},"reference":[{"issue":"21","key":"zoi200346r1","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1001\/jama.295.21.2483","article-title":"Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial.","volume":"295","author":"Aoyama","year":"2006","journal-title":"JAMA"},{"issue":"11","key":"zoi200346r2","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/S1470-2045(09)70263-3","article-title":"Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.","volume":"10","author":"Chang","year":"2009","journal-title":"Lancet Oncol"},{"issue":"5","key":"zoi200346r3","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.ijrobp.2017.07.045","article-title":"Stereotactic radiosurgery with or without whole-brain radiation therapy for limited brain metastases: a secondary analysis of the North Central Cancer Treatment Group N0574 (Alliance) randomized controlled trial.","volume":"99","author":"Churilla","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"zoi200346r4","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2010.30.1655","article-title":"Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study.","volume":"29","author":"Kocher","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9","key":"zoi200346r5","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.6004\/jnccn.2013.0132","article-title":"Central nervous system cancers.","volume":"11","author":"Nabors","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"key":"zoi200346r6","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/annonc\/mdp152","article-title":"Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up.","volume":"20","author":"Dummer","year":"2009","journal-title":"Ann Oncol"},{"issue":"3","key":"zoi200346r7","doi-asserted-by":"publisher","first-page":"250","DOI":"10.6004\/jnccn.2009.0020","article-title":"Melanoma.","volume":"7","author":"Coit","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"zoi200346r8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3747\/co.6","article-title":"Temozolomide for the treatment of metastatic melanoma.","volume":"14","author":"Quirt","year":"2007","journal-title":"Curr Oncol"},{"issue":"8","key":"zoi200346r9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma.","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"issue":"26","key":"zoi200346r10","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation.","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi200346r11","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial.","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"issue":"11","key":"zoi200346r12","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol"},{"issue":"1","key":"zoi200346r13","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10552-015-0690-5","article-title":"Comprehensive capture of cutaneous melanoma by the Ontario Cancer Registry: validation study using community pathology reports.","volume":"27","author":"Tran","year":"2016","journal-title":"Cancer Causes Control"},{"issue":"5","key":"zoi200346r14","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/0895-4356(88)90052-2","article-title":"An application of capture-recapture methods to the estimation of completeness of cancer registration.","volume":"41","author":"Robles","year":"1988","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"zoi200346r17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data.","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"issue":"10","key":"zoi200346r18","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.clon.2018.05.005","article-title":"A population-based study of survival impact of new targeted and immune-based therapies for metastatic or unresectable melanoma.","volume":"30","author":"Hanna","year":"2018","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"10","key":"zoi200346r19","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1093\/annonc\/mdu266","article-title":"On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases.","volume":"25","author":"Gaudy-Marqueste","year":"2014","journal-title":"Ann Oncol"},{"issue":"2","key":"zoi200346r20","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ijrobp.2015.01.004","article-title":"Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment.","volume":"92","author":"Kiess","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9829","key":"zoi200346r21","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.","volume":"379","author":"Falchook","year":"2012","journal-title":"Lancet"},{"issue":"8","key":"zoi200346r22","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","article-title":"Combined nivolumab and ipilimumab in melanoma metastatic to the brain.","volume":"379","author":"Tawbi","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi200346r23","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.adro.2017.07.003","article-title":"Distant intracranial failure in melanoma brain metastases treated with stereotactic radiosurgery in the era of immunotherapy and targeted agents.","volume":"2","author":"Acharya","year":"2017","journal-title":"Adv Radiat Oncol"},{"issue":"2","key":"zoi200346r24","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ijrobp.2012.05.002","article-title":"A multi-institutional study of factors influencing the use of stereotactic radiosurgery for brain metastases.","volume":"85","author":"Hodgson","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"33","key":"zoi200346r25","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1200\/JCO.19.01414","article-title":"Adjuvant whole-brain radiation therapy compared with observation after local treatment of melanoma brain metastases: a multicenter, randomized phase III trial.","volume":"37","author":"Hong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi200346r26","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jama.2016.9839","article-title":"Effect of radiosurgery alone vs radiosurgery with whole brain radiation therapy on cognitive function in patients with 1 to 3 brain metastases: a randomized clinical trial.","volume":"316","author":"Brown","year":"2016","journal-title":"JAMA"},{"issue":"5","key":"zoi200346r27","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","article-title":"Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.","volume":"19","author":"Long","year":"2018","journal-title":"Lancet Oncol"},{"key":"zoi200346r15","unstructured":"Statistics Canada. August 2015 postal codes. Postal Code Conversion File Plus (PCCF+). Version 6C. Catalog no. 82-E0086-XDB. Canadian Research Data Centre Network; 2016. Accessed May 12, 2017. https:\/\/crdcn.org\/datasets\/pccf-postal-code-conversion-file"},{"key":"zoi200346r16","unstructured":"Kralj? B. Measuring rurality\u2014RIO 2008_BASIC: methodology and results. Ontario Medical Association Economics Department; 2009. Accessed May 12, 2017. http:\/\/www.eriestclairlhin.on.ca\/Page.aspx?id=11606"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2767882\/brastianos_2020_oi_200346.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T15:42:57Z","timestamp":1594050177000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2767882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,6]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.8204","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,6]]}}}